WallStSmart

Insmed Inc (INSM)vsQuoin Pharmaceuticals Ltd DRC (QNRX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

QNRX leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

QNRX

Avoid

25

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

QNRX0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

QNRX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$13.19M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : QNRX

QNRX has a balanced fundamental profile.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : QNRX

The primary concerns for QNRX are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while QNRX is a value play — different risk/reward profiles.

QNRX carries more volatility with a beta of 1.82 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

QNRX generates stronger free cash flow (-2M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Quoin Pharmaceuticals Ltd DRC

HEALTHCARE · BIOTECHNOLOGY · USA

Quoin Pharmaceuticals Ltd (QNRX) is a biotechnology firm focused on developing innovative therapeutics for rare diseases and unmet medical needs. Utilizing advanced drug delivery technologies, the company enhances the efficacy and safety of established compounds, solidifying its position within the specialty pharmaceuticals sector. Quoin's robust pipeline includes therapies aimed at critical conditions, paving the way for potential clinical advancements and market opportunities. As the company progresses through its clinical trials, it remains dedicated to fostering value for both patients and shareholders through strategic collaborations and cutting-edge research initiatives.

Want to dig deeper into these stocks?